ReachMD Healthcare Image
Media formats available:
  • Overview

    Dive into the cutting-edge realm of bispecific antibodies for relapsed/refractory multiple myeloma with our experts, Dr. Caitlin Costello and Dr. Sagar Lonial. They explore the efficacy, safety, and practical integration of bispecific antibodies into clinical practice. Tune in to gain invaluable insights on optimizing patient care and navigating treatment-related adverse events to elevate your oncology practice. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Caitlin Costello, MD 
    Associate Clinical Professor of Medicine
    University of California, San Diego
    La Jolla, CA 

    Dr. Costello has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, BMS, Janssen, Karyopharm, Pfizer, Regeneron, Takeda
    Research: BMS, Harpoon, Ionis, Janssen, Pfizer, Poseida, Takeda 

    Sagar Lonial, MD, FACP 
    Chair and Professor 
    Department of Hematology and Medical Oncology
    Anne and Bernard Gray Family Chair in Cancer
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, GA 

    Dr. Lonial has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, Amgen, BMS, Genentech, GSK, Janssen, Novartis, Pfizer, Regeneron 

    Reviewers/Content Planners/Authors: 

    • Stephen Chavez has nothing to disclose. 
    • Cindy Davidson has nothing to disclose. 
    • Wilma Guerra has nothing to disclose.  
    • Libby Lurwick has nothing to disclose. 
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
    • Tim Person has nothing to disclose.  
    • Colleen Resnick has nothing to disclose. 
    • Mara Siegel has nothing to disclose. 
    • Bing-E Xu has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:  

    • Recognize the adverse event profile of bispecific antibodies used for the treatment of relapsed and refractory multiple myeloma (RRMM) 
    • Employ strategies in treatment planning, including prophylaxis and step-up dosing, to prevent adverse events associated with the use of bispecific antibodies for RRMM 
  • Target Audience

    This activity is designed to meet the educational needs of hematology/oncology physicians, advanced practice providers, pathologists, emergency medicine physicians, hospitalists, and pharmacists. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for.25 AAPA Category 1 CME credits. Approval is valid until March 7, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.   

    Global Learning Collaborative (GLC) designates this activity for
    .25 contact hours/0.025 CEUs of pharmacy contact hours.1 
    The Universal Activity Number for this program is JA0006235-0000-24-018-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (  

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.  

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by an educational grant from Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free